Highlights form the Tenth Annual Scientific Meeting of the American
Society of Hypertension will be made available FREE via the ASH-EHLB mail list.
To subscribe and receive information about this meeting, highlights
delivered to your email address during the meeting and a chance to
communicate with presenters, send a subscribe message (SUBSCRIBE
SUBSCRIBE John Doe
Meanwhile, here is the schedule pf sessions for:
SATURDAY, MAY 20
================
10:00 AM to 12:00 PM
--------------------
Theme I: Heart and {*filter*} Vessels
Cloning Angiotensin II Responsive Genes in Vascular
Smooth Muscle
Mark Taubman, MD, New York, NY
Original Communications
Theme II: Clinical Pharmacology of Antihypertensive {*filter*}
Circadian Regulation of {*filter*} Pressure: Mechanisms and
Therapeutic Implications
Bjorn Lemmer, MD, Frankfurt, Germany
Original Communications
Theme III: Clinical Hypertension
Transition from Clinical Trials to Clinical Practice
Peter Sleight, MD, Oxford, England
Original Communications
1:00 PM to 3:00 PM
------------------
Theme I: RENAL MECHANISMS IN HYPERTENSION
Chronic Renal Failure
Howard Jacob, PhD, Charlestown, MA
Renal Medullary Mechanisms in Hypertension
Richard J. Roman, PhD, Milwaukee, WI
Nitric Oxide Mediation of Pressure Natriuresis
L. Gabriel Navar, PhD, New Orleans, LA
Dopamine Signaling Defects in SHR
Pedro A. Jose, MD, PhD, Washington, DC
Autocrine Inhibition of Renal Epithelial Na+/K+ ATPase by
Nitric Oxide
Nicolas J. Guzman, MD, Gainesville, FL
Discussion
Theme II: HOW LOW SHOULD {*filter*} PRESSURE BE?
Epidemiology
Astrid Fletcher, PhD, London, England
Kidney
Paul K. Whelton, MD, MSc, Baltimore, MD
Heart and Vessels
Diederick E. Grobbee, MD, PhD, Rotterdam, The Netherlands
Treatment and Myocardial Ischemia
John M. Cruickshank, MD, Cheshire, England
Discussion
1:00 PM to 4:30 PM
Theme III: CLINICAL TRIALS NEW FINDINGS FROM COMPLETED STUDIES
AND FUTURE DIRECTIONS
TOHMS
Richard H. Grimm, Jr, MD, PhD, Minneapolis, MN
Update on the VA Cooperative Study Group on Antihypertensive
Agents: Monotherapy of Hypertension Trial
Barry J. Materson, MD, MBA, Miami, FL
SHEP
Jeffrey L. Probstfield, MD, Seattle, WA
New Trials on Antihypertensive {*filter*} Outside the United
States
Lennart Hansson, MD, Uppsala, Sweden
Panel Discussion
ALLHAT
Jackson T. Wright, Jr, MD, PhD, Cleveland, OH
Prevention and Treatment of Hypertension Study (PATHS):
{*filter*} Reduction for Hypertension and Upper Normal {*filter*}
Pressure
William C. Cushman, MD, Memphis, TN
Clinical Trials with Ambulatory {*filter*} Pressure Monitoring:
Evidence from the Syst-Eur Trial
Jan A. Staessen, MD, PhD, Leuven, Belgium
Panel Discussion
3:00 PM to 5:00 PM
------------------
Theme I: ANGIOTENSIN-DEPENDENT MECHANISMS IN HYPERTENSION
Ren 2 Transgenic Rat Model of Hypertension
To Be Announced
Renal Mechanisms of Hypertension in the Ren 2 Transgenic Rat
Kenneth D. Mitchell, PhD, New Orleans, LA
Angiotensin (1-7): A Novel Hormone of the RAS
Carlos Ferrario, MD, Winston-Salem, NC
Chymase-Dependent Angiotension II Forming System in Humans
Hidenori Urata, MD, Berlin, Germany
Mechanisms of Angiotensin II Mediated Intracellular
Signaling
Kenneth E. Bernstein, MD, Atlanta, GA
Discussion
Theme II: NEW INSIGHTS INTO RENOVASCULAR HYPERTENSION
Which Diagnostic Tests Are Best For Ischemic Nephropathy?
Samuel J. Mann, MD, New York, NY
The Role of Surgery in the Treatment of Ischemic Nephropathy
Richard H. Dean, MD, Winston-Salem, NC
The Role of Angioplasty and Stents in the Treatment of
Ischemic Nephropathy
Thomas Sos, MD, New York, NY
Ischemic Nephropathy: The Medical Viewpoint
Marc A. Pohl, MD, Cleveland, OH
Discussion
--
John Mack
----------------------------------------------
John Mack 1-215-949-0490
Pharmaceutical Information Associates, Ltd.
2761 Trenton Road, Levittown, PA 19056 USA
Creators of PharmInfoNet, a Web site devoted to pharmaceutical information.
URL: http://www.***.com/
-----------------------------------------------